CCR9 and CCL25: A review of their roles in tumor promotion

Xu, Bin; Deng, Chao; Wu, Xue; Ji, Ting; Zhao, Lin; Han, Yuehu; Yang, Wenwen; Qi, Yating; Wang, Zheng; Yang, Zhi; Yang, Yang

doi:10.1002/jcp.29782

Cited by 38 publications

(20 citation statements)

References 100 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…There are no data on the influence of CCL25 on the recruitment of cells cooperating in the development of a tumor or its participation in angiogenesis [ 297 ]. However, this chemokine may cause infiltration of the tumor by cytotoxic TIL exhibiting CCR9 expression, which has an anticancer effect [ 298 ].…”

Section: Ccr9 and Ccl25mentioning

confidence: 99%

CC Chemokines in a Tumor: A Review of Pro-Cancer and Anti-Cancer Properties of Receptors CCR5, CCR6, CCR7, CCR8, CCR9, and CCR10 Ligands

Korbecki

Grochans

Gutowska

et al. 2020

IJMS

238

176

View full text Add to dashboard Cite

CC chemokines (or β-chemokines) are 28 chemotactic cytokines with an N-terminal CC domain that play an important role in immune system cells, such as CD4+ and CD8+ lymphocytes, dendritic cells, eosinophils, macrophages, monocytes, and NK cells, as well in neoplasia. In this review, we discuss human CC motif chemokine ligands: CCL1, CCL3, CCL4, CCL5, CCL18, CCL19, CCL20, CCL21, CCL25, CCL27, and CCL28 (CC motif chemokine receptor CCR5, CCR6, CCR7, CCR8, CCR9, and CCR10 ligands). We present their functioning in human physiology and in neoplasia, including their role in the proliferation, apoptosis resistance, drug resistance, migration, and invasion of cancer cells. We discuss the significance of chemokine receptors in organ-specific metastasis, as well as the influence of each chemokine on the recruitment of various cells to the tumor niche, such as cancer-associated fibroblasts (CAF), Kupffer cells, myeloid-derived suppressor cells (MDSC), osteoclasts, tumor-associated macrophages (TAM), tumor-infiltrating lymphocytes (TIL), and regulatory T cells (Treg). Finally, we show how the effect of the chemokines on vascular endothelial cells and lymphatic endothelial cells leads to angiogenesis and lymphangiogenesis.

show abstract

Section: Ccr9 and Ccl25mentioning

confidence: 99%

CC Chemokines in a Tumor: A Review of Pro-Cancer and Anti-Cancer Properties of Receptors CCR5, CCR6, CCR7, CCR8, CCR9, and CCR10 Ligands

Korbecki

Grochans

Gutowska

et al. 2020

IJMS

238

176

View full text Add to dashboard Cite

show abstract

“…CCR9 and its specific ligand CCL25 are categorized as a mucosal chemokine system, which is responsible for recruiting a subset of T cells to the lamina propria of the small intestine (Kunkel et al, 2000;Norment et al, 2000;Vicari et al, 1997;Zlotnik & Yoshie, 2012). The axis of CCL-25-CCR9 has been investigated as a therapeutic target of Crohn's disease, tumors, and autoimmunity (Biswas et al, 2019;Korbecki et al, 2020;Pathak & Lal, 2020;Xu et al, 2020). CXCR6 regulates localization of tissue-resident memory CD8 T cells to the airways throughout the sustained immune response to airway pathogens such as influenza viruses (Wein et al, 2019).…”

Section: Another Recent Report By Enard and Petrov Proposed Thatmentioning

confidence: 99%

Genetic variation analyses indicate conserved SARS‐CoV‐2–host interaction and varied genetic adaptation in immune response factors in modern human evolution

Lee

Sato

et al. 2021

Dev Growth Differ

View full text Add to dashboard Cite

Coronavirus disease 2019 (COVID‐19), caused by severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2), is a pandemic as of early 2020. Upon infection, SARS‐CoV‐2 attaches to its receptor, that is, angiotensin‐converting enzyme 2 (ACE2), on the surface of host cells and is then internalized into host cells via enzymatic machineries. This subsequently stimulates immune response factors. Since the host immune response and severity of COVID‐19 vary among individuals, genetic risk factors for severe COVID‐19 cases have been investigated. Our research group recently conducted a survey of genetic variants among SARS‐CoV‐2‐interacting molecules across populations, noting near absence of difference in allele frequency spectrum between populations in these genes. Recent genome‐wide association studies have identified genetic risk factors for severe COVID‐19 cases in a segment of chromosome 3 that involves six genes encoding three immune‐regulatory chemokine receptors and another three molecules. The risk haplotype seemed to be inherited from Neanderthals, suggesting genetic adaptation against pathogens in modern human evolution. Therefore, SARS‐CoV‐2 uses highly conserved molecules as its virion interaction, whereas its immune response appears to be genetically biased in individuals to some extent. We herein review the molecular process of SARS‐CoV‐2 infection as well as our further survey of genetic variants of its related immune effectors. We also discuss aspects of modern human evolution.

show abstract

“…Chronic hypoxia does not affect CCL25/thymus-expressed chemokine (TECK) expression, as shown in lung adenocarcinoma cells [13] and hepatocellular carcinoma cells [143]. Nevertheless, the expression of CCL25/TECK occurs mainly in the gastrointestinal tract in physiological conditions [242]. Therefore research is needed on the effect of hypoxia on gastric cancer and colon cancer.…”

Section: Effect Of Hypoxia On the Ccl25/teck→ccr9 Axis In A Tumormentioning

confidence: 99%

Hypoxia Alters the Expression of CC Chemokines and CC Chemokine Receptors in a Tumor–A Literature Review

Korbecki

Kojder

Barczak

et al. 2020

IJMS

View full text Add to dashboard Cite

Hypoxia, i.e., oxygen deficiency condition, is one of the most important factors promoting the growth of tumors. Since its effect on the chemokine system is crucial in understanding the changes in the recruitment of cells to a tumor niche, in this review we have gathered all the available data about the impact of hypoxia on β chemokines. In the introduction, we present the chronic (continuous, non-interrupted) and cycling (intermittent, transient) hypoxia together with the mechanisms of activation of hypoxia inducible factors (HIF-1 and HIF-2) and NF-κB. Then we describe the effect of hypoxia on the expression of chemokines with the CC motif: CCL1, CCL2, CCL3, CCL4, CCL5, CCL7, CCL8, CCL11, CCL13, CCL15, CCL16, CCL17, CCL18, CCL19, CCL20, CCL21, CCL22, CCL24, CCL25, CCL26, CCL27, CCL28 together with CC chemokine receptors: CCR1, CCR2, CCR3, CCR4, CCR5, CCR6, CCR7, CCR8, CCR9, and CCR10. To better understand the effect of hypoxia on neoplastic processes and changes in the expression of the described proteins, we summarize the available data in a table which shows the effect of individual chemokines on angiogenesis, lymphangiogenesis, and recruitment of eosinophils, myeloid-derived suppressor cells (MDSC), regulatory T cells (Treg), and tumor-associated macrophages (TAM) to a tumor niche.

show abstract

CCR9 and CCL25: A review of their roles in tumor promotion

Cited by 38 publications

References 100 publications

CC Chemokines in a Tumor: A Review of Pro-Cancer and Anti-Cancer Properties of Receptors CCR5, CCR6, CCR7, CCR8, CCR9, and CCR10 Ligands

CC Chemokines in a Tumor: A Review of Pro-Cancer and Anti-Cancer Properties of Receptors CCR5, CCR6, CCR7, CCR8, CCR9, and CCR10 Ligands

Genetic variation analyses indicate conserved SARS‐CoV‐2–host interaction and varied genetic adaptation in immune response factors in modern human evolution

Hypoxia Alters the Expression of CC Chemokines and CC Chemokine Receptors in a Tumor–A Literature Review

Contact Info

Product

Resources

About